Core Points - Linkage Global Inc has announced a private investment in public equity (PIPE) financing, issuing 689,655 Class A Ordinary Shares at a price of US$1.45 per share, resulting in total gross proceeds of approximately US$1,000,000 [1][2][3] - The PIPE is expected to close on or before December 3, 2025, subject to customary closing conditions [2] - The net proceeds from the offering will be used for general corporate purposes, including working capital needs and expansion of cross-border sales operations [3] Company Overview - Linkage Global Inc is a holding company incorporated in the Cayman Islands, operating through subsidiaries in Japan, Hong Kong, and mainland China, focusing on cross-border e-commerce integrated services [5] - The company has developed a comprehensive service system with two complementary lines of business: cross-border sales and integrated e-commerce services [5] Management Commentary - The CEO of Linkage Global, Yang (Angela) Wang, stated that the PIPE financing is a significant milestone for the company, enhancing its financial position and supporting its strategic objectives [4]

Core Viewpoint - Quorum Information Technologies Inc. has received shareholder approval for a statutory plan of arrangement with 2745122 Alberta Inc., an affiliate of Valsoft Corporation Inc., indicating a significant corporate restructuring move [1][2][3]. Group 1: Shareholder Approval - A total of 58,584,797 Common Shares were represented at the special meeting, accounting for 79.55% of the issued and outstanding shares [2]. - Approximately 97.65% of the votes cast were in favor of the special resolution approving the arrangement [2]. Group 2: Court Approval and Next Steps - The Court of King's Bench of Alberta has granted a final order approving the arrangement, which is a critical step in the process [3]. - The completion of the arrangement is contingent upon satisfying or waiving remaining conditions outlined in the arrangement agreement dated September 22, 2025, including final approval from the TSX Venture Exchange [3]. Group 3: Company Overview - Quorum Information Technologies Inc. is a North American SaaS company providing essential enterprise solutions for automotive dealerships and Original Equipment Manufacturers [5]. - The company offers a range of products including a Dealership Management System, DealerMine CRM, Autovance, Accessible Accessories, and VINN Automotive, all aimed at enhancing dealership operations and customer satisfaction [5][6].

Core Insights - Avante Corp. reported a 10% year-over-year revenue growth for the second quarter of fiscal 2026, driven by significant increases in its NSSG and Avante Black divisions, which grew by 47% and 48% respectively [2][4][5] - The company achieved Adjusted EBITDA of $0.58 million, marking a 73% increase compared to the same quarter in the previous fiscal year, and recorded a net income of $0.08 million, a turnaround from a net loss of $0.9 million in the prior year [4][5][7] - Avante maintains a positive outlook for fiscal 2026, anticipating organic growth across its service offerings, including Avante Black, HALO, Avante Verified, and MAST [4][5] Financial Performance - Consolidated revenue for the second quarter reached $8.88 million, up from $8.09 million in the same quarter last year, with a gross profit of $3.7 million, reflecting a 7% increase [5][7] - The recurring monthly revenues (RMR) for the second quarter were reported at $4.2 million, a 14% increase year-over-year, attributed to growth in monitoring customers and new recurring revenue services [5][7] - Operating expenses declined year-over-year, indicating effective cost-management initiatives, including the implementation of a new ERP system [2][5] Operational Highlights - The NSSG division is gaining international momentum with active projects across multiple continents, showcasing the company's expanding global footprint [2] - The rebranding of the HALO-powered ecosystem's monitoring solution from WALL-E to MAST signifies the company's commitment to innovation in security technology [2] - Avante's strong balance sheet remains debt-free, with $4.2 million in cash and $12 million in available credit facilities, providing a solid foundation for future growth [2][5]

CALGARY, Alberta, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Acceleware® Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE) announces financial and operating results for the three and nine months ended September 30, 2025. This news release should be read in conjunction with the Company’s unaudited interim condensed financial statements and the accompanying notes for the nine months ended September 30, 2025, and management’s discussion and analysis (“MD&A”) thereto, together with the audited financial statements for t ...

Core Insights - HUTCHMED will present new and updated data from several studies at the upcoming ESMO Asia Congress 2025 and ASH Annual Meeting, showcasing its commitment to advancing cancer therapies [1][2][3] Group 1: Upcoming Presentations - A first-in-human study of HMPL-A83, an anti-CD47 monoclonal antibody, will be presented, focusing on advanced solid tumors [2] - The phase II results of the FRUSICA-2 study, evaluating the combination of fruquintinib and sintilimab for renal cell carcinoma, will also be shared [2] - Surufatinib's phase II results in combination with camrelizumab and chemotherapy for metastatic pancreatic cancer will be reported [2] Group 2: Specific Study Details - HMPL-A83 presentation details include a mini oral session on December 7, 2025, led by Ye Guo [2] - Fruquintinib's results will be presented by Shanshan Wang on December 5, 2025, in a proffered paper session [2] - Surufatinib's study will be displayed as a poster by Shukui Qin [2] Group 3: Additional Studies - Several investigator-initiated studies will also be presented, including combinations of fruquintinib with other treatments for metastatic colorectal cancer [3] - The final analysis of the ESLIM-01 study on sovleplenib for chronic primary immune thrombocytopenia will be presented at the ASH Annual Meeting [3] Group 4: Product Information - Fruquintinib is a selective oral inhibitor of VEGFRs, co-developed by HUTCHMED and Eli Lilly, marketed as ELUNATE in China [4] - HMPL-A83 is a humanized anti-CD47 monoclonal antibody that disrupts cancer cells' immune evasion [5] - Savolitinib is a selective MET tyrosine kinase inhibitor developed by AstraZeneca and HUTCHMED, marketed as ORPATHYS [6] - Surufatinib is an oral angio-immuno kinase inhibitor marketed as SULANDA in China [7] - Sovleplenib is a selective small molecule inhibitor targeting Syk, with potential applications in B-cell lymphomas [8]

Core Insights - Hydreight Technologies Inc. reported significant financial growth in Q3 2025, with a focus on expanding its VSDHOne platform and achieving strategic objectives for 2026 [1][5][10] Financial Performance - For the first nine months of 2025, topline revenue reached CAD 26.71 million, a 61% increase year-over-year, while GAAP revenue was CAD 20.44 million, up 70% [5][7] - Q3 2025 topline revenue was CAD 12.83 million, marking a 110% increase compared to Q3 2024, with GAAP revenue at CAD 10.52 million, a 132% increase [5][7] - Q3 2025 gross margin improved to CAD 2.33 million from CAD 1.53 million in Q3 2024, and adjusted EBITDA was CAD 620K, indicating continued operational improvement [5][7] - The company reported a GAAP net income of CAD 362K in Q3 2025, a significant turnaround from a net loss of CAD 90K in Q3 2024 [5][7] Business Development - Hydreight processed approximately 295,000 VSDHOne product orders between July and September 2025, reflecting broad growth across various wellness verticals [5][10] - The nurse network expanded with 198 new sign-ups in Q3 2025, a 49% increase year-over-year, totaling 593 sign-ups in the first nine months of 2025, up 63% from 2024 [5][10] - Pharmacy orders increased by approximately 72% year-over-year, indicating sustained growth and broader adoption of services [5][10] Strategic Initiatives - The company signed a definitive agreement to acquire a 5% equity stake in Perfect Scripts, LLC, with an option to increase to 40%, establishing a strategic partnership [5][10] - Hydreight is actively evaluating profitable multi-state wellness and digital health operators for potential acquisitions to scale nationally through the VSDHOne platform [5][10] - The upcoming release of VSDHOne V2 aims to enhance automation, scalability, and modular functionality for partners nationwide [5][10] Recognition and Awards - Hydreight was recognized as one of Canada's Technology Fast 50™ award winners and ranked 77 among the fastest-growing companies in North America on the 2025 Deloitte Technology Fast 500™ [5][10]

Core Points - Transgene has requested the suspension of trading of its shares on Euronext Paris pending the publication of the results of its capital increase, with trading set to resume on 27 November 2025 [1] Company Overview - Transgene is a biotechnology company focused on developing targeted immunotherapies for cancer treatment, with a portfolio of viral vector-based immunotherapeutics [2] - The company's lead asset is TG4050, an individualized therapeutic vaccine based on the myvac® platform, which has shown proof of principle in treating head and neck cancers [2] - Transgene is also developing other viral vector-based assets, including BT-001, an oncolytic virus in clinical development, and is engaged in innovative discovery and preclinical work for novel viral vector-based modalities [2] Technology and Innovation - The myvac® platform allows for the creation of personalized virus-based immunotherapies that encode patient-specific mutations identified through advanced AI technologies [3] - Transgene's proprietary Invir.IO® platform is aimed at designing a new generation of multifunctional oncolytic viruses, leveraging the company's expertise in viral vector engineering [4]

Core Points - Transgene successfully raised approximately €105 million through a fundraising initiative involving private placements and retail offerings at a price of €1.02 per share [1][6][10] - The funds will primarily support the development of the myvac® platform, which focuses on individualized therapeutic vaccines for cancer treatment [4][5][7] - The fundraising included participation from specialized healthcare investors and existing shareholders, indicating strong institutional interest [2][21] Fundraising Details - The fundraising consisted of a private placement and a public offering via the PrimaryBid platform, with a total of 141,433,349 new ordinary shares issued, representing 106.5% of the company's current share capital [9][10] - The subscription price of €1.02 per share reflects a 25% discount compared to the closing price prior to the fundraising [10] - A reserved capital increase of €39,262,015.44 was also conducted for TSGH, utilizing amounts advanced under a current account advance agreement [3][12] Use of Proceeds - Approximately 70% of the net proceeds will be allocated to accelerate the myvac® program, including ongoing Phase 2 trials and the launch of new indications [7][5] - About 20% will be directed towards R&D costs related to the myvac® program and other clinical trials [7] - The remaining funds will cover general administrative expenses and recurring cash consumption [7] Expected Milestones - Key milestones include the completion of the ongoing Phase 2 trial in head and neck cancers, with results anticipated by late 2027 or early 2028 [4][15] - The company plans to launch a Phase 1 trial in a new indication and prepare for pivotal trials by the end of 2027 [15][4] Share Capital and Ownership Structure - Post-fundraising, the company's share capital will amount to €82,256,012.70, divided into 274,186,709 ordinary shares [18] - TSGH will hold 78.29% of the capital, while SITAM Belgium will hold 3.55%, with other shareholders comprising 18.16% [18][21] Trading and Regulatory Information - Trading of Transgene's shares on Euronext Paris was suspended during the fundraising and is set to resume on November 27, 2025 [23][24] - The new shares will be fungible with existing shares and will carry the same rights [25]

VANCOUVER, British Columbia, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Liberty Gold Corp. (TSX:LGD; OTCQX:LGDTF) ("Liberty Gold" or the "Company") is pleased to announce that the United States Forest Service (“USFS”) and the United States Bureau of Land Management (“BLM”) have determined that the Mine Plan of Operations (“MPO”) for the Company’s flagship Black Pine Oxide Gold Project (“Black Pine” or the “Project”) in southern Idaho has met federal content standards and is deemed “Administratively Complete” under T ...

Core Points - American Lithium Corp. held its Annual General Meeting of Shareholders in Vancouver, where all nominees for the Board of Directors were elected with significant support [1][2][3] - Shareholders approved the number of directors to be fixed at six, the appointment of Davidson & Company LLP as the auditor, and the re-approval of the Company's omnibus incentive plan [2][3] Voting Results - The voting results for the election of the Board of Directors showed high approval rates, with Andrew Bowering receiving 98.77% of votes for, and Claudia Tornquist receiving 93.26% [1] - The number of directors was approved with 97.72% of votes for, while the appointment of auditors received 97.46% approval [3] Company Overview - American Lithium is developing two major lithium projects and the largest undeveloped uranium project in Latin America, including the TLC claystone lithium project in Nevada and the Falchani hard rock lithium project in Peru [4]